These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 32252809)

  • 1. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
    de Jesus AA; Hou Y; Brooks S; Malle L; Biancotto A; Huang Y; Calvo KR; Marrero B; Moir S; Oler AJ; Deng Z; Montealegre Sanchez GA; Ahmed A; Allenspach E; Arabshahi B; Behrens E; Benseler S; Bezrodnik L; Bout-Tabaku S; Brescia AC; Brown D; Burnham JM; Caldirola MS; Carrasco R; Chan AY; Cimaz R; Dancey P; Dare J; DeGuzman M; Dimitriades V; Ferguson I; Ferguson P; Finn L; Gattorno M; Grom AA; Hanson EP; Hashkes PJ; Hedrich CM; Herzog R; Horneff G; Jerath R; Kessler E; Kim H; Kingsbury DJ; Laxer RM; Lee PY; Lee-Kirsch MA; Lewandowski L; Li S; Lilleby V; Mammadova V; Moorthy LN; Nasrullayeva G; O'Neil KM; Onel K; Ozen S; Pan N; Pillet P; Piotto DG; Punaro MG; Reiff A; Reinhardt A; Rider LG; Rivas-Chacon R; Ronis T; Rösen-Wolff A; Roth J; Ruth NM; Rygg M; Schmeling H; Schulert G; Scott C; Seminario G; Shulman A; Sivaraman V; Son MB; Stepanovskiy Y; Stringer E; Taber S; Terreri MT; Tifft C; Torgerson T; Tosi L; Van Royen-Kerkhof A; Wampler Muskardin T; Canna SW; Goldbach-Mansky R
    J Clin Invest; 2020 Apr; 130(4):1669-1682. PubMed ID: 31874111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Validated Interferon Score Using NanoString Technology.
    Kim H; de Jesus AA; Brooks SR; Liu Y; Huang Y; VanTries R; Montealegre Sanchez GA; Rotman Y; Gadina M; Goldbach-Mansky R
    J Interferon Cytokine Res; 2018 Apr; 38(4):171-185. PubMed ID: 29638206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.
    Rider LG; Shah M; Mamyrova G; Huber AM; Rice MM; Targoff IN; Miller FW;
    Medicine (Baltimore); 2013 Jul; 92(4):223-243. PubMed ID: 23877355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
    Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.
    Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS
    Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.
    Kim H
    Curr Opin Rheumatol; 2021 Sep; 33(5):371-377. PubMed ID: 34230439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.
    Wienke J; Deakin CT; Wedderburn LR; van Wijk F; van Royen-Kerkhof A
    Front Immunol; 2018; 9():2951. PubMed ID: 30619311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
    Kim H; Sanchez GA; Goldbach-Mansky R
    J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
    J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies.
    Cappelletti C; Baggi F; Zolezzi F; Biancolini D; Beretta O; Severa M; Coccia EM; Confalonieri P; Morandi L; Mora M; Mantegazza R; Bernasconi P
    Neurology; 2011 Jun; 76(24):2079-88. PubMed ID: 21670437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.
    Melki I; Devilliers H; Gitiaux C; Bondet V; Duffy D; Charuel JL; Miyara M; Bokov P; Kheniche A; Kwon T; Authier FJ; Allenbach Y; Belot A; Bodemer C; Bourrat E; Dumaine C; Fabien N; Faye A; Frémond ML; Hadchouel A; Kitabayashi N; Lepelley A; Martin-Niclos MJ; Mudumba S; Musset L; Quartier P; Rice GI; Seabra L; Uettwiller F; Uggenti C; Viel S; Rodero MP; Crow YJ; Bader-Meunier B
    Rheumatology (Oxford); 2020 Aug; 59(8):1927-1937. PubMed ID: 31755959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis.
    Karasawa R; Yudoh K; Sato T; Tanaka M; Tamaki M; Sabbagh SE; O'Hanlon TP; Noroozi-Farhadi P; Targoff IN; Flegel WA; Mammen AL; Miller FW; Hicar MD; Rider LG; Jarvis JN
    Rheumatology (Oxford); 2022 Jul; 61(7):2969-2977. PubMed ID: 34791087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis.
    Gitiaux C; Latroche C; Weiss-Gayet M; Rodero MP; Duffy D; Bader-Meunier B; Glorion C; Nusbaum P; Bodemer C; Mouchiroud G; Chelly J; Germain S; Desguerre I; Chazaud B
    Arthritis Rheumatol; 2018 Jan; 70(1):134-145. PubMed ID: 28941175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies.
    Perron MM; Vasquez-Canizares N; Tarshish G; Wahezi DM
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):92. PubMed ID: 34118936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.
    Ono N; Kai K; Maruyama A; Sakai M; Sadanaga Y; Koarada S; Inoue T; Tada Y
    Rheumatology (Oxford); 2019 May; 58(5):786-791. PubMed ID: 30541137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
    Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
    Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
    [No Abstract]   [Full Text] [Related]  

  • 18. Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.
    Kim H; Huber AM; Kim S
    Rheum Dis Clin North Am; 2021 Nov; 47(4):669-690. PubMed ID: 34635298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Tansley SL; Betteridge ZE; Gunawardena H; Jacques TS; Owens CM; Pilkington C; Arnold K; Yasin S; Moraitis E; Wedderburn LR; McHugh NJ;
    Arthritis Res Ther; 2014 Jul; 16(4):R138. PubMed ID: 24989778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.